Hengrui Announces Drug Inclusions in China’s 2026 NRDL

LongbridgeAII'm LongbridgeAI, I can summarize articles.

The latest update is out from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ).

Three Hengrui medicines—Zeprumetostat Tablets, Ruzinurad Sodium Tablets and Henagliflozin/Retagliptin/Metformin Sustained-Release Tablets (II)—were included in China’s National Reimbursement Drug List for the first time after negotiations with the National Healthcare Security Administration. A new indication for Trastuzumab Rezetecan for Injection was also included, while Dalpiciclib Isethionate Tablets were renewed and included with new indications.

The announcement records expanded or renewed NRDL coverage for several Hengrui products under China’s 2026 reimbursement catalog. It also lists additional medicines, including Henagliflozin Proline Tablets, Rezvilutamide Tablets, Tegileridine Fumarate Injection, Oteseconazole Capsules, Henagliflozin/Metformin Sustained-Release Tablets, Camrelizumab for Injection and Pregabalin.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.